Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis

Stavas J.Thajudeen B.b· Coca S.c· Silva A.d· Butler E.a· Detwiler R.e· Burgner A.f

Author affiliations

aProKidney, Raleigh, NC, USA
bDepartment of Medicine, Banner University of Arizona School of Medicine, Tucson, AZ, USA
cDepartment of Medicine, Icahn School of Medicine at Mt. Sinai, New York, NY, USA
dBoise Kidney and Hypertension, Boise, ID, USA
eDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
fDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: March 17, 2022
Accepted: October 11, 2022
Published online: January 04, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 4

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Introduction: Cell-based therapies potentially delay the trajectory toward end-stage kidney disease (ESKD) in late stage 4 diabetic chronic kidney disease (DKD). We describe the trial design, baseline patient characteristics, and early results of an IRB-approved phase II multicenter clinical trial, utilizing Renal Autologous Cell Therapy (REACT) in adults with pre-ESKD due to type 2 DKD. The trial objectives were safety and tolerability of REACT by assessment of the procedure, product administration, and renal-specific adverse events in addition to evaluate the impact on renal function following injection. Methods: Ten adults with an eGFR of 14–20 mL/min/1.73 m2 were enrolled in a single-arm open-label trial. Following a percutaneous kidney biopsy, an ex vivo expansion of selected renal cells that form the REACT was injected into the cortex of the biopsied kidney with CT image guidance. Each participant received two doses of the REACT product at 6-month intervals. A 6-month observation pre-trial was required to establish patients’ “own” baseline and rate of DKD progression. Results: Five men and 5 women underwent 19 REACT injections (1 participant received only one injection). Their baseline characteristics were as follows: 3 Hispanic/Latino, 7 non-Hispanic, 7 white; mean (SD) age: 58.9 years (5.22), BMI 35.8 (8.2), eGFR (sCR) 15.5 (2.72), eGFR (sCR + Cys-C) 17.7 (3.67) mL/min/1.73 m2, sCr 3.6 mg/mL (0.73), Cys-C 2.6 mg/mL (0.52), and log random UACR 7.9 mg/g (1.01). The pre- and post-injection eGFR slope was −6.5 mL/min/1.73 m2 and −3.9 mL/min/1.73 m2. No cell-related adverse events occurred, and two procedure-related hematomas required observation without transfusion or angiographic interventions. Dialysis was delayed a mean of 16 months (range 6–28 months). At 15 months, 2 patients (20%) have eGFR slope stability and have not commenced renal replacement therapy. Conclusion: Trials that include patients with an eGFR of <20 mL/min/1.73 m2 are uncommon, and none to date involve autologous homologous cell-based treatments. REACT has the potential to stabilize or delay dialysis in high-risk late stage 4 DKD.

© 2023 S. Karger AG, Basel

References Jepson C, Hsu JY, Fischer MJ, Kusek JW, Lash JP, Ricardo AC, et al. Incident type 2 diabetes among individuals with CKD: findings from the chronic renal Insufficiency cohort (CRIC) Study. Am J Kidney Dis. 2019;73(1):72–81. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8(1):29. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int. 2005;67(2):404–19. Papazova DA, Oosterhuis NR, Gremmels H, van Koppen A, Joles JA, et al. Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis. Dis Model Mech. 2015;8(3):281–93. Hickson LJ, Abedalqader T, Ben-Bernard G, Mondy JM, Bian X, Conley SM, et al. A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease. Stem Cells Transl Med. 2021;10(9):1304–19. United States Renal Data System Annual Report. Chapter 9: healthcare expenditures for persons with ESRD. Available from: https://adr.usrds.org/2020/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd (accessed February 21, 2022). Kelley R, Werdin ES, Bruce AT, Choudhury S, Wallace SM, Ilagan RM, et al. Tubular cell-enriched subpopulation of primary renal cells improves survival and augments kidney function in rodent model of chronic kidney disease. Am J Physiol Renal Physiol. 2010;299(5):F1026–1039. Kelley R, Bruce A, Spencer T, Werdin E, Ilagan R, Choudhury S, et al. A population of selected renal cells augments renal function and extends survival in the ZSF1 model of progressive diabetic nephropathy. Cell Transpl. 2013;22(6):1023–39. Stenvinkel P, Wadstrom J, Bertram T, Detwiler R, Gerber D, Brismar TB, et al. Implantation of autologous selected renal cells in diabetic chronic kidney disease stages 3 and 4: clinical experience of a “first in human” study. Kidney Int Rep. 2016;1:105–13. Stavas J, Gerber D, Coca SG, Silva AL, Johns A, Jain D, et al. Novel renal autologous cell therapy for type 2 diabetes mellitus chronic diabetic didney disease: clinical trial design. Am J Nephrol. 2022 Jan 14:1–9. Yu H, Sonntag PD, Bream PR, Lazarowicz MP, Nowakowski FS, Woodhead GJ, et al. Safety and feasibility of a novel percutaneous locoregional injection technique of renal cellular therapy for chronic kidney disease of diabetes. Kidney Int Rep. 2021 Jun 19;6(9):2486–90. American Society of Nephrology. Abstract 3611676 “REACT® for Type 2 D-CKD: preliminary results with renal cortex implantation” ASN 2021. 2021. Tangri N, Stevens L, Griffith J, Tighiouart H, Djurdev O, Naimark D. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553–9. QxMD. Kidney risk failure equation (8 variable). Available from: https://qxmd.com/calculate/calculator_125/kidney-failure-risk-equation-8-variable (accessed February 21, 2022). Vonesh E, Tighiouart H, Ying J, Heerspink HL, Lewis J, Staplin N, et al. Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med. 2019;38(22):4218–39. Ku E, Johansen KL, McCulloch CE. Time-centered approach to understanding risk factors for the progression of CKD. Clin J Am Soc Nephrol. 2018;13(5):693–701. Bruce AT, Ilagan RM, Guthrie KI, Rivera E, Choudhury S, Sangha N, et al. Selected renal cells modulate disease progression in rodent models of chronic kidney disease via NF-κB and TGF-β1pathways. Regen Med. 2015;10(7):815–39. Basu J, Genheimer CW, Rivera EA, Payne R, Mihalko K, Guthrie K, et al. Functional evaluation of primary renal cell/biomaterial neo-kidney augment prototypes for renal tissue engineering. Cell Transpl. 2011;20(11–12):1771–90. Betts KA, Song J, Faust E, Yang K, Du Y, Kong SX. Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2021;27(20 Suppl):S369–S374. Ku E, McCulloch C, Johansen K. Starting renal replacement therapy: it it about time? Am J Nephrol. 2019;50(2):144–51. U.S. National Library of Medicine; Prokidney. A study of REACT® in subjects with type 1 and type 2 diabetes and chronic kidney disease. Available from: https://clinicaltrials.gov/ct2/show/NCT05018416 (accessed February 21, 2022). Stavas J, Diaz-Gonzalez de Ferris M, Johns A, Jain D, Bertram T. Protocol and baseline data on renal autologous cell therapy injection in adults with chronic kidney disease secondary to congenital anomalies of the kidney and urinary tract. Blood Purif. 2021;50(4–5):678–83. Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: March 17, 2022
Accepted: October 11, 2022
Published online: January 04, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 4

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif